SeaStar Medical Holding Corporation (NASDAQ:ICU) Sees Large Increase in Short Interest
by Teresa Graham · The Cerbat GemSeaStar Medical Holding Corporation (NASDAQ:ICU – Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 215,212 shares, a growth of 28.1% from the March 15th total of 167,946 shares. Approximately 5.4% of the shares of the company are sold short. Based on an average trading volume of 318,775 shares, the days-to-cover ratio is presently 0.7 days.
Institutional Investors Weigh In On SeaStar Medical
Several large investors have recently modified their holdings of the stock. Trinity Financial Advisors LLC raised its stake in shares of SeaStar Medical by 233.3% during the third quarter. Trinity Financial Advisors LLC now owns 50,000 shares of the company’s stock worth $28,000 after purchasing an additional 35,000 shares during the last quarter. XTX Topco Ltd raised its stake in shares of SeaStar Medical by 395.4% during the second quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after purchasing an additional 48,674 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of SeaStar Medical during the fourth quarter worth approximately $30,000. Finally, Millennium Management LLC purchased a new stake in shares of SeaStar Medical during the third quarter worth approximately $102,000. Hedge funds and other institutional investors own 1.69% of the company’s stock.
SeaStar Medical Trading Up 1.0%
Shares of SeaStar Medical stock traded up $0.04 during trading hours on Friday, hitting $4.20. 263,101 shares of the company were exchanged, compared to its average volume of 269,425. SeaStar Medical has a 1 year low of $2.07 and a 1 year high of $13.40. The business has a 50-day moving average of $2.95 and a 200-day moving average of $3.55. The stock has a market capitalization of $16.76 million, a price-to-earnings ratio of -0.51 and a beta of -1.21.
SeaStar Medical (NASDAQ:ICU – Get Free Report) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.17. SeaStar Medical had a negative return on equity of 188.47% and a negative net margin of 984.60%.The business had revenue of $0.42 million during the quarter, compared to analysts’ expectations of $0.22 million.
Analysts Set New Price Targets
ICU has been the subject of several research analyst reports. Wall Street Zen raised SeaStar Medical to a “hold” rating in a report on Saturday, January 10th. Maxim Group set a $6.00 price objective on SeaStar Medical in a report on Thursday, February 12th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of SeaStar Medical in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell” and a consensus target price of $6.00.
View Our Latest Analysis on ICU
SeaStar Medical Company Profile
SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.
The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.